Last reviewed · How we verify

NCT04033627

TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

Status unknown NA Last updated 29 September 2022
What this trial tests

NA trial testing In Vitro T cells depletion using CliniMCAS system in Relapsed Pediatric ALL in 30 participants. Status unknown.

Timeline
10 November 2020
Primary endpoint
18 July 2022
8 May 2024

Quick facts

Lead sponsorShanghai Children's Medical Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date10 November 2020
Primary completion18 July 2022
Estimated completion8 May 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Children's Medical Center

Who can join

Adults 2 Months to 18, any sex, with Relapsed Pediatric ALL or Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center clinical study in China using CliniMACS TCRα/β+ and CD45RA+ T cell depleted stem cell grafts from haploidentical donors for hematopoietic stem cell transplantation in children.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Relapsed Pediatric ALL

Currently open trials in the same condition.

Other Shanghai Children's Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04033627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing